{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:44:20Z","timestamp":1782744260369,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.yebeh.2020.107456","type":"journal-article","created":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T19:35:20Z","timestamp":1604259320000},"page":"107456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The improvement in diagnosis and epilepsy managing in children with progressive myoclonus epilepsy during the last decade \u2014 A tertiary center experience in cohort of 51 patients"],"prefix":"10.1016","volume":"113","author":[{"given":"Ruzica","family":"Kravljanac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Vucetic Tadic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Lalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Kravljanac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Cerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107456_bb0005","series-title":"Progressive myoclonus epilepsies: state of the art","first-page":"1","article-title":"The history of progressive myoclonus epilepsies","author":"Genton","year":"2017"},{"key":"10.1016\/j.yebeh.2020.107456_bb0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.seizure.2019.08.012","article-title":"The best evidence for progressive myoclonic epilepsy: a pathway to precision therapy","volume":"71","author":"Orsini","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107456_bb0015","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s00415-010-5641-1","article-title":"Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects","volume":"257","author":"de Siqueira","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2020.107456_bb0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1212\/WNL.0000000000000077","article-title":"Progressive myoclonic epilepsies \u2014 definitive and still undetermined causes","volume":"82","author":"Franceschetti","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.107456_bb0025","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajhg.2011.04.004","article-title":"Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6","volume":"88","author":"Arsov","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.yebeh.2020.107456_bb0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pediatrneurol.2012.05.004","article-title":"Mutation of the CLN6 gene in teenage-onset progressive myoclonus epilepsy","volume":"47","author":"Andrade","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2020.107456_bb0035","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus \u2014 report of ILAE Task Force in classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107456_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neulet.2017.05.014","article-title":"Recent advances in epilepsy genetics","volume":"667","author":"Orsini","year":"2018","journal-title":"Neurosci Lett"},{"issue":"9 S2","key":"10.1016\/j.yebeh.2020.107456_bb0045","first-page":"28","article-title":"Unverricht\u2013Lundborg disease","volume":"18","author":"Crespel","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2020.107456_bb0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/TCRM.S241048","article-title":"Changing times for CLN2 disease: the era of enzyme replacement therapy","volume":"16","author":"Specchio","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.yebeh.2020.107456_bb0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management strategies for CLN2 disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2020.107456_bb0060","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study","volume":"2","author":"Nickel","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.yebeh.2020.107456_bb0065","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymgme.2016.07.011","article-title":"Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis","volume":"119","author":"Fietz","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.yebeh.2020.107456_bb0070","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107456_bb0075","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/epi.13820","article-title":"Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease","volume":"58","author":"Specchio","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107456_bb0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/jnnp.40.4.323","article-title":"So-called neuronal ceroid lipofuscinosis","volume":"40","author":"Pampiglione","year":"1977","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2020.107456_bb0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eplepsyres.2018.05.005","article-title":"Late-onset childhood neuronal ceroid lipofuscinosis: early clinical and electroencephalographic markers","volume":"144","author":"Beltr\u00e1na","year":"2018","journal-title":"Epilepsy Res"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2020.107456_bb0090","first-page":"S145S153","article-title":"Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials","volume":"18","author":"Michelucci","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2020.107456_bb0095","first-page":"307","article-title":"Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood","volume":"95","author":"Medina","year":"2005","journal-title":"Adv Neurol"},{"key":"10.1016\/j.yebeh.2020.107456_bb0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0887-8994(01)00350-2","article-title":"Chloral hydrate for progressive myoclonus epilepsy: a new look at an old drug","volume":"25","author":"Pranzattelli","year":"2001","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2020.107456_bb0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","article-title":"Current and emerging treatment strategies for neuronal ceroid lipofuscinoses","volume":"33","author":"Kohlsch\u00fctter","year":"2019","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.yebeh.2020.107456_bb0110","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/0883073819895694","article-title":"Review of cerliponase alfa: recombinant human enzyme replacement therapy for late-infantile neuronal ceroid lipofuscinosis type 2","volume":"35","author":"Lewis","year":"2020","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2020.107456_bb0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1684\/epd.2012.0501","article-title":"Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam","volume":"14","author":"Fernandez-Baca Vaca","year":"2012","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2020.107456_bb0120","first-page":"70","article-title":"Epileptic motor status in progressive myoclonus epilepsy: efficacy of IV phenytoin","volume":"38","author":"Riguzzi","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107456_bb0125","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1528-1167.2008.01546.x","article-title":"Clinical picture of EPM1-Unverricht\u2013Lundborg disease","volume":"49","author":"K\u00e4lvi\u00e4inen","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107456_bb0130","doi-asserted-by":"crossref","first-page":"801809","DOI":"10.1016\/j.eplepsyres.2009.02.010","article-title":"Reassessment of phenytoin for treatment of late stage progressive myoclonus epilepsy complicated with status epilepticus","volume":"84","author":"Miyahara","year":"2009","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.yebeh.2020.107456_bb0135","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ejpn.2015.05.007","article-title":"Etiology, clinical course and response to the treatment of status epilepticus in children: a 16-year single-center experience based on 602 episodes of status epilepticus","volume":"19","author":"Kravljanac","year":"2015","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020306363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020306363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:34:55Z","timestamp":1761503695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020306363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":27,"alternative-id":["S1525505020306363"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107456","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The improvement in diagnosis and epilepsy managing in children with progressive myoclonus epilepsy during the last decade \u2014 A tertiary center experience in cohort of 51 patients","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107456"}}